News

PDS Biotechnology Corp (PDSB) – Phase 2 Treatment Continues As New Patient Recruitment Is Delayed

Health
0 min read

Friday, October 22, 2021

PDS Biotechnology Corp (PDSB)
Phase 2 Treatment Continues As New Patient Recruitment Is Delayed

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is primarily engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Current Patients Unaffected As Recruitment Is Suspended.  POn Oct 21, PDSB announced that recruitment of new patients for the National Cancer Institute (NCI)-led Phase 2 clinical trial (NCT04287868) has been suspended. In a conversation with management, we learned that the action was related to updates to the informed consent document used by the NCI, which the company referred to as administrative purposes. Patients previously enrolled in the trial are not affected and continue to receive treatment.

    Only One of Three Trials Is Affected. The trial impacted is the Phase 2 evaluating PDS0101 (Versamune-HPV16) in a triple combination for advanced HPV cancers . The trial is sponsored by the National Cancer Institute and is testing PDS0101 with two other…



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Share

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2024 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.